Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects. Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
View Top Employees from Calistoga PharmaceuticalsWebsite | http://www.calistogapharma.com |
Revenue | $8.4 million |
Employees | 6 (6 on RocketReach) |
Founded | 2006 |
Address | 2101 Fourth Ave suite 1960, Seattle, Washington 98121, US |
Phone | (206) 728-4700 |
Technologies | |
Industry | Biotechnology, Pharmaceuticals, Alternative Medicine, Healthcare, Health Care, Drug Manufacturing & Research, Science and Engineering, Medical |
SIC | SIC Code 283 Companies, SIC Code 28 Companies, SIC Code 2834 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 32541 Companies |
Looking for a particular Calistoga Pharmaceuticals employee's phone or email?
The Calistoga Pharmaceuticals annual revenue was $8.4 million in 2024.
6 people are employed at Calistoga Pharmaceuticals.
Calistoga Pharmaceuticals is based in Seattle, Washington.
The NAICS codes for Calistoga Pharmaceuticals are [325, 3254, 32, 32541].
The SIC codes for Calistoga Pharmaceuticals are [283, 28, 2834].